secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-07-24T21:01:05+00:00
Accession:  0001104659-26-086685
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics receives FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD
--------------------------------------------------------------------------------

- LYTENAVA is the first and only FDA-approved ophthalmic bevacizumab for wet AMD in the US.
- Company anticipates 12 years of Reference Product Exclusivity under the BPCIA.
- US anti-VEGF retina market estimated at ~$8.5B annually; commercial launch expected before year-end.
- CEO Bob Jahr: approval establishes a new standard for bevacizumab therapy in wet AMD.
- LYTENAVA already approved in EU and UK; US approval adds a major market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/0001104659-26-086685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-086685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer